logo

Protalix Biotherapeutics Inc. (PLX)



Trade PLX now with
  Date
  Headline
6/8/2020 5:01:22 PM Protalix BioTherapeutics Appoints Yael Hayon As Its VP, Research And Development
6/1/2020 6:52:19 AM Protalix BioTherapeutics Q1 EPS $0.10 Vs Loss $0.50 Last Year
5/28/2020 6:52:08 AM Protalix BioTherapeutics Announces Submission Of BLA To FDA For Pegunigalsidase Alfa
5/11/2020 6:54:12 AM Protalix Reports Positive Topline Results From Phase III BRIDGE Clinical Trial Of PRX-102
3/16/2020 6:53:36 AM Protalix Agrees To Conduct Feasibility Study With Kirin On Production Of Novel Complex Protein
3/12/2020 8:07:45 AM Protalix BioTherapeutics Q4 Net Profit $0.3 Mln Or $0.02 Per Share
3/12/2020 7:59:26 AM Protalix BioTherapeutics Announces $43.7 Mln In Financing To Further Advance Its Programs In Fabry Disease
2/6/2020 6:52:19 AM Protalix, Chiesi Farmaceutici Announce Receipt Of Agreement Letter For Initial Pediatric Study Plan For PRX-102
12/19/2019 6:51:50 AM Protalix BioTherapeutics Appoints Pol Boudes And Gwen Melincoff To Its Board
12/9/2019 4:07:05 PM Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
11/27/2019 6:52:08 AM Protalix BioTherapeutics Hosts Key Opinion Leader Meeting On PRX-102 Drug Candidate
11/18/2019 6:58:05 AM Protalix BioTherapeutics And Chiesi Complete Successful Pre-BLA Meeting With FDA For Pegunigalsidase Alfa